Connect with us

Technology

Lumia Health™ Debuts World’s First Wearable for Tracking Blood Flow to Your Head at CES 2025

Published

on

 Clinically demonstrated wearable tracks blood flow to your head to help people with chronic illnesses better understand and self-manage symptoms caused by poor blood flow, now backed by $10.4M in funding and strong beta user engagement.

BOSTON, Jan. 6, 2025 /PRNewswire/ — Lumia Health™ is debuting the world’s first wearable that tracks blood flow to the head at CES 2025 (January 7-10) in Eureka Park, Venetian Expo. The Lumia™ wearable is designed to help people better understand and self-manage chronic symptoms of dizziness, brain fog, fatigue, and fainting made worse by standing*. Since emerging from stealth in 2023, the company completed a 30-day $560,000 crowdfunding campaign, sold out of pre-order inventory, secured more than $3.6M in contracts with multiple government agencies, and completed shipments to its Beta customers.

Clinically Shown to have Strong Correlation with Gold Standard Ultrasound and Symptoms

Clinically tested at top institutions like Johns Hopkins, Duke, and Harvard Medical School, Lumia™ technology has been refined by the world’s top experts in blood flow monitoring. Published at the 2024 American Autonomic Society Conference, the Lumia™ technology has been clinically shown to correlate strongly with the gold standard, Transcranial Doppler ultrasound, with a Pearson correlation of 0.91 for Carotid Flow Time, a measure of blood flow to the head. At the 2024 Dysautonomia International Conference, Lumia Flow Index™ was found to correlate better with orthostatic symptoms than traditional heart rate metrics, earning the Patient’s Choice Award.

Usefulness Demonstrated by Strong User Engagement Metrics

Hundreds of Lumia™ Beta testers are already finding immense value in the unprecedented blood flow data, demonstrating exceptional engagement with over 12 hours of daily wear time and over 40 minutes of daily mobile app use, proving its utility as a self-help tool. The biofeedback helps Lumia™ members see how lifestyle factors such as posture, hydration, compression garments, and other daily activities affect blood flow to their head, improving self-awareness and encouraging lifestyle adjustments to avoid exacerbating symptoms.

Unlocking the Next Evolutionary Step in Wearables with All-Day Blood Flow Tracking

The Lumia™ wearable weighs less than 1 gram and is more than 5 times smaller than Apple Airpods. It tracks blood flow by tapping into a shallow artery in the ear, a branch of the External Carotid Artery, which runs parallel to the brain’s primary blood supply. This strong arterial signal is crucial to enabling the wearable’s unprecedented cardiac data. Unlike wrist wearables which suffer from data corruption due to arm movement, the Lumia™ wearable allows users to track blood flow through various activities of daily living. Most users comment that the wearable is so comfortable and unobtrusive that they completely forget they are wearing it.

“Blood flow to the head is the critical missing vital sign for millions suffering from chronic illnesses affected by dizziness, lightheadedness, brain fog, fatigue, and fainting made worse by standing,” said Lumia Health™ Cofounder and CEO, Daniel Lee. “After almost 5 years, we’ve finally unlocked the potential of the ear to track it in a user-friendly wearable, offering unparalleled insights into these often misunderstood illnesses. While we are focused on chronic brain blood flow illnesses to start, our preliminary research shows that multi-day blood flow monitoring also has the potential to revolutionize many of healthcare’s costliest conditions, from fainting and falling in older adults, to improving in-patient fluid management for sepsis and heart failure**. At CES 2025, we are excited to find partners to help us expand the impact that this groundbreaking technology can have.”

From Stealth to CES

Since its launch, Lumia Health has raised $10.4 million in funding, with additional venture financing and government research contracts. The wearable has undergone a variety of clinical pilot tests at top medical institutions, and has been published in the Journal of the American College of Cardiology and the American Autonomic Society.

Join us at booth 62047 in Eureka Park at the Venetian Expo to experience the future of wearables. The team will be offering real-time demos of its blood flow tracking technology. Learn how to rapidly drop the blood flow to your head to experience what dizziness feels like for those with chronic brain blood flow illnesses such as POTS, Dysautonomia, Orthostatic Hypotension, Long COVID, ME/CFS, and Orthostatic Intolerance!

How to Order

Due to high demand, Lumia™ wearables are currently still sold out. Sales will re-open on February 4th at 10AM Eastern, with deliveries starting in March 2025. Save the date and visit www.lumiahealth.com to sign up for email notifications to be among the first to reserve your Lumia™ wearable. Quantities will be limited, and orders will be shipped in the order they are received, so we encourage early reservations to secure your wearable.

About Lumia Health™ 

Lumia Health™, formerly known as STAT Health, is a digital health company improving the quality of life for people living with chronic cardiovascular and neurological diseases, starting with chronic illnesses experiencing drops in blood flow upon standing. Lumia Health™ does this through its hardware platform — the ear wearable – and targeted software programs built atop its unparalleled longitudinal cardiac data. Founded in 2020, Lumia Health™ is backed by leading venture capital firms, government grants, and a growing community of early adopters. The founders, Daniel Lee and Paul Jin, previously ran Bose’s Health Product Innovation Group, and Lee was the inventor of Bose sleepbuds™.

For more information, visit www.lumiahealth.com. For logos, photos and facts, visit our online Media Kit.

*  The initial software app is not intended for medical diagnostic or treatment purposes. It is designed and marketed to comply with the FDA General Wellness Guidance1 and Device Software Functions and Mobile Medical Application Guidance2.

** These proposed indications are research areas under exploration with preliminary feasibility data, and are not cleared or approved by regulatory authorities.

Media Contact
Shivani Ugrin
shivani@lumiahealth.com 
928-614-1065

Click here for more details about our booth at: https://ces25.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=001Pp00000f4LRFIA2.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumia-health-debuts-worlds-first-wearable-for-tracking-blood-flow-to-your-head-at-ces-2025-302343308.html

SOURCE Lumia Health™

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network

Published

on

By

Latest independent ranking reinforces Bell’s network leadership

MONTRÉAL, July 20, 2026 /CNW/ — Bell today announced that its 5G+ network has been ranked Canada’s Fastest 5G+ Network by independent network analysts Rohde & Schwarz SwissQual AG (R&S), adding to its growing list of independent network awards.

Bell ranked first in both R&S’s Fastest 5G+ Network Data Speed Performance Score and Fastest 5G Network Data Speed Score categories based on extensive drive testing across 19 Canadian communities. The recognition builds on Bell’s recent Ookla awards for Canada’s Fastest and Best 5G Network, reinforcing Bell’s position as a leader in wireless performance through both real-world consumer testing and independent engineering analysis.

Bell’s network delivers during the moments that matter most, from everyday connections with family, friends and colleagues to Canada’s biggest cultural and sporting events. Built to perform even when demand is at its highest, Bell’s 5G+ network helped keep customers connected during major events this year, including the Formula 1 Grand Prix in Montréal, the Canadiens’ playoff run and Canada’s summer of soccer.

Since 2020, Bell has invested billions in broadband and wireless infrastructure, expanding its network with faster speeds, greater reliability and advanced capabilities for communities across Canada. This year alone, Bell has upgraded hundreds of towers from 4G to 5G with more on the way.

Quotes

“This recognition from Rohde & Schwarz is another strong validation of Bell’s strategic priority to deliver the best networks. Bell’s 5G+ network delivers the speed and performance Canadians expect, whether they’re streaming, gaming, working or staying connected on the go. Connection is everything, and we’re proud to see our continued investment recognized by another independent third party.”

–    Blaik Kirby, Group President, Consumer and Small Business, Bell

“Based on our 2026 testing of national wireless networks in Canada, Bell delivered the top 5G/5G+ data performance, meaning subscribers can experience faster speeds and more reliable connections, especially in busy urban areas. At Rohde & Schwarz, independent network benchmarking is core to our mission. By providing operators with objective, real-world performance data, we help drive continuous improvement across the industry, ultimately benefiting every subscriber.”

–    Axel Hansmann, CEO Rohde & Schwarz SwissQual AG

To learn more about 5G and 5G+ wireless, please visit Bell.ca/network.

About Bell
Bell is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

1 Based on total revenue and total combined customer connections.

Media inquiries: 
Patricia Garcia
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

SOURCE Bell Canada (MTL)

Continue Reading

Technology

Bell’s wireless earns top marks from Rohde & Schwarz as Canada’s Fastest 5G+ Network

Published

on

By

Latest independent ranking reinforces Bell’s network leadership

MONTRÉAL, July 20, 2026 /CNW/ — Bell today announced that its 5G+ network has been ranked Canada’s Fastest 5G+ Network by independent network analysts Rohde & Schwarz SwissQual AG (R&S), adding to its growing list of independent network awards.

Bell ranked first in both R&S’s Fastest 5G+ Network Data Speed Performance Score and Fastest 5G Network Data Speed Score categories based on extensive drive testing across 19 Canadian communities. The recognition builds on Bell’s recent Ookla awards for Canada’s Fastest and Best 5G Network, reinforcing Bell’s position as a leader in wireless performance through both real-world consumer testing and independent engineering analysis.

Bell’s network delivers during the moments that matter most, from everyday connections with family, friends and colleagues to Canada’s biggest cultural and sporting events. Built to perform even when demand is at its highest, Bell’s 5G+ network helped keep customers connected during major events this year, including the Formula 1 Grand Prix in Montréal, the Canadiens’ playoff run and Canada’s summer of soccer.

Since 2020, Bell has invested billions in broadband and wireless infrastructure, expanding its network with faster speeds, greater reliability and advanced capabilities for communities across Canada. This year alone, Bell has upgraded hundreds of towers from 4G to 5G with more on the way.

Quotes

“This recognition from Rohde & Schwarz is another strong validation of Bell’s strategic priority to deliver the best networks. Bell’s 5G+ network delivers the speed and performance Canadians expect, whether they’re streaming, gaming, working or staying connected on the go. Connection is everything, and we’re proud to see our continued investment recognized by another independent third party.”

–    Blaik Kirby, Group President, Consumer and Small Business, Bell

“Based on our 2026 testing of national wireless networks in Canada, Bell delivered the top 5G/5G+ data performance, meaning subscribers can experience faster speeds and more reliable connections, especially in busy urban areas. At Rohde & Schwarz, independent network benchmarking is core to our mission. By providing operators with objective, real-world performance data, we help drive continuous improvement across the industry, ultimately benefiting every subscriber.”

–    Axel Hansmann, CEO Rohde & Schwarz SwissQual AG

To learn more about 5G and 5G+ wireless, please visit Bell.ca/network.

About Bell
Bell is Canada’s largest communications company1, leading the way in advanced fibre and wireless networks, enterprise services and digital media. By delivering next-generation technology that leverages cloud-based and AI-driven solutions, we’re keeping customers connected, informed and entertained while enabling businesses to compete on the world stage. To learn more, please visit Bell.ca or BCE.ca.

1 Based on total revenue and total combined customer connections.

Media inquiries: 
Patricia Garcia
media@bell.ca

Investor inquiries:
Krishna Somers
krishna.somers@bell.ca

SOURCE Bell Canada (MTL)

Continue Reading

Technology

Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

Published

on

By

Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care’s FDA 510(k)-cleared software platform for kidney replacement therapy in the United StatesAggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability

BAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ — Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, the Company’s FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise is designed to provide retrospective, program-level insight into kidney replacement therapy (KRT) delivered in acute and hospital critical care settings.

Kidney replacement therapy in the Intensive Care Unit (ICU) generates large volumes of clinical and operational data, yet trends related to therapy delivery, workflow interruptions, and alarm frequency can be difficult to assess without standardized metrics and aggregated views. TherapyWise consolidates existing data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods.

“Digital solutions play an increasingly important role in how critical care teams understand and manage complex therapies,” said Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care. “TherapyWise reflects our continued focus on innovation in critical care by applying data analytics. This helps hospital and clinical leaders gain visibility into how kidney replacement therapy is delivered across their organizations, supporting informed discussions around workflow, consistency, and quality improvement.”

TherapyWise works by securely transmitting data from the NxStage System One with NxView to a cloud‑based platform, where information is aggregated and displayed across predefined performance indicators. These include program‑level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended to support retrospective review and program oversight and is not designed for real‑time, patient‑specific clinical decision‑making, which remains the responsibility of attending clinicians.

TherapyWise is part of Fresenius Medical Care’s NxView 4.0 software platform and broader critical care portfolio, which combines digital infrastructure, clinical expertise, and secure data management to support hospital teams responsible for kidney replacement therapy programs.

To learn more about TherapyWise, please visit https://freseniusmedicalcare.com/en-us/products/critical-care/therapywise/.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-therapy-302829320.html

SOURCE Fresenius Medical Care Holdings, Inc.

Continue Reading

Trending